Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 15/20 | 0.59 |
| ▸ | DRD4 | P21917 | 15/20 | 0.59 |
| ▸ | DRD3 | P35462 | 15/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808659 | 1.00 | POLB (0.60) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL6419291 | 0.90 | MEN1 (0.66) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL29456062 | 0.84 | POLB (0.64) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL933584 | 0.84 | POLB (0.64) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL14277003 | 0.82 | POLB (0.61) | POLBDRD2DRD4DRD3CHRM2 | |
| SCHEMBL18350824 | 0.82 | MEN1 (0.62) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL8025555 | 0.81 | HTR2A (0.60) | POLBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL5661091 | 0.79 | CHRM2 (0.67) | POLBDRD2DRD4DRD3CHRM2 | |
| SCHEMBL5385733 | 0.79 | POLB (0.66) | POLBMEN1KMT2ADRD2DRD4 | |
| SCHEMBL30483504 | 0.79 | DRD2 (0.69) | POLBDRD2DRD4DRD3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | POLB 4858/4885KDM4E 2337/4885MEN1 1590/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | POLB 4839/4885KDM4E 2472/4885MEN1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.